Genocure Co., Ltd. (CEO Bo-kyung Oh), a company specializing in regenerative medical biomaterials, held a CDMO-MSA contract signing ceremony for ‘recombinant PDRN’ at the Asymchem headquarters in China on Friday, November 22.
Reflecting the high interest of the Chinese authorities, a number of government officials, including Jao Jing, director of the Tianjin City Drug Supervision and Administration Bureau, also attended the event.
Genocure said, “Based on our own technology that can extract and produce PDRN with high purity, we have succeeded in developing ‘recombinant PDRN’, a next-generation PDRN production technology, and obtained results that are 100% identical to salmon DNA, the raw material for existing PDRN, at Blast of NCBI in the United States. “He said. Based on this achievement, the company signed a CDMO-MSA contract with AsimChem for technological advancement, GMP process development, and mass production of ‘recombinant PDRN’.
Regarding the meaning of this contract, an official from the company said, “We will enter the 300 trillion won global regenerative medicine market dominated by hyaluronic acid through mass production of ‘recombinant PDRN’, a groundbreaking technology that overcomes the shortage of PDRN due to biological limitations that have been pointed out so far. “We have laid the foundation to do it,” he said.
Founded in 1997, AsimChem has strengthened its global status as a CDMO for the COVID-19 ‘Pfizer vaccine’ and is recording annual sales of 3 trillion won. As more than 70% of sales come from global pharmaceutical companies, it is a comprehensive solution provider in the CDMO field that has established itself as a key partner in the bio and pharmaceutical industries by building trust through cutting-edge technology and strict quality control.
Regarding the signing of this contract, Genocure CEO Oh Bo-kyung said, “The CDMO-MSA contract with AsimChem, a global CDMO company, means that Genocure’s technology has been recognized,” and added, “China-Korea-USA-Europe in 2025. Starting with market entry and sales, we expanded Genocure’s PDRN position into the global regenerative medicine market worth KRW 300 trillion, and also developed a ‘recombinant PDRN’ application with AsimChem. “We will also strive to expand the pipeline,” he expressed his ambition.
Source: www.nextdaily.co.kr
